Cargando…

Technical Feasibility and Safety of Repeated Computed Tomography–Guided Transthoracic Intratumoral Injection of Gene-Modified Cellular Immunotherapy in Metastatic NSCLC

INTRODUCTION: To assess the technical feasibility and safety of repeated percutaneous computed tomography (CT)–guided transthoracic biopsies and intratumoral injections of gene-modified dendritic cells in metastatic NSCLC. METHODS: A total of 15 patients with 15 NSCLC lesions measuring greater than...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shahrouki, Puja, Lee, Jay M., Barclay, Jonathan, Khan, Sarah N., Genshaft, Scott, Abtin, Fereidoun, Dubinett, Steven M., Lisberg, Aaron, Sharma, Sherven, Garon, Edward B., Suh, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581369/ https://www.ncbi.nlm.nih.gov/pubmed/34806054 http://dx.doi.org/10.1016/j.jtocrr.2021.100242

Ejemplares similares

PD-L1 expression correlates with immune response in a Phase I trial of CCL21 gene modified dendritic cell therapy in lung cancer
por: Lee, Jay M, et al.
Publicado: (2014)

Intratumoral Treatment with Chemotherapy and Immunotherapy for NSCLC with EBUS-TBNA 19G
por: Zarogoulidis, Paul, et al.
Publicado: (2021)

CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunity
por: Salehi-Rad, Ramin, et al.
Publicado: (2023)

Outcomes with multi-disciplinary management of central lung tumors with CT-guided percutaneous high dose rate brachyablation
por: Yoon, Stephanie M., et al.
Publicado: (2021)

Novel CCL21-Vault Nanocapsule Intratumoral Delivery Inhibits Lung Cancer Growth
por: Kar, Upendra K., et al.
Publicado: (2011)

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)
por: Brahmer, Julie R., et al.
Publicado: (2018)

Targeting MDSCs enhance therapeutic vaccination responses against lung cancer
por: Srivastava, Minu K., et al.
Publicado: (2012)

Predictors of Invasiveness in Adenocarcinoma of Lung with Lepidic Growth Pattern
por: Young, Timothy J., et al.
Publicado: (2022)

The Non-Coding Oncogene: A Case of Missing DNA Evidence?
por: Shahrouki, Puja, et al.
Publicado: (2012)

Intratumoral Immunotherapy—Update 2019
por: Hamid, Omid, et al.
Publicado: (2019)

Trial watch: intratumoral immunotherapy
por: Humeau, Juliette, et al.
Publicado: (2021)

Immunotherapeutic Agents for Intratumoral Immunotherapy
por: Shyr, Chih-Rong, et al.
Publicado: (2023)

Increased PD-L1 expression in KRAS mutated premalignant human bronchial epithelial cells is enhanced by LKB1 loss and mediated by ERK activation
por: Lee, Mi-Heon, et al.
Publicado: (2015)

Intratumoral TNFα improves immunotherapy
por: Johansson, Anna, et al.
Publicado: (2012)

Characterization of intratumor microbiome in cancer immunotherapy
por: Zhang, Zhao, et al.
Publicado: (2023)

Understanding Intratumor Heterogeneity and Evolution in NSCLC and Potential New Therapeutic Approach
por: Goto, Taichiro, et al.
Publicado: (2018)

Repurposing infectious disease vaccines for intratumoral immunotherapy
por: Melero, Ignacio, et al.
Publicado: (2020)

Repurposing the yellow fever vaccine for intratumoral immunotherapy
por: Aznar, Maria Angela, et al.
Publicado: (2019)

The Contemporary Landscape and Future Directions of Intratumoral Immunotherapy
por: Brito-Orama, Sebastian, et al.
Publicado: (2023)

The Malignant Pleural Effusion as a Model to Investigate Intratumoral Heterogeneity in Lung Cancer
por: Basak, Saroj K., et al.
Publicado: (2009)

CCL21 Cancer Immunotherapy
por: Lin, Yuan, et al.
Publicado: (2014)

The Role of PPARγ in the Cyclooxygenase Pathway in Lung Cancer
por: Hazra, Saswati, et al.
Publicado: (2008)

Transthoracic biopsy of lung masses: Non technical factors affecting complication occurrence
por: Aktas, Aykut Recep, et al.
Publicado: (2015)

Simple and effective bacterial-based intratumoral cancer immunotherapy
por: Carroll, Christina S E, et al.
Publicado: (2021)

Intratumoral cancer immunotherapy exploiting anti-viral immunity
por: Kadowaki, Norimitsu
Publicado: (2021)

The Landscape of Immunotherapy Resistance in NSCLC
por: Frisone, Daniele, et al.
Publicado: (2022)

Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level
por: Guo, Longhua, et al.
Publicado: (2019)

IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a STAT1-dominant pathway in human non-small cell lung cancer
por: Kachroo, Puja, et al.
Publicado: (2013)

Supratentorial extraventricular anaplastic ependymoma in an adult with repeated intratumoral hemorrhage
por: Iwamoto, Naotaka, et al.
Publicado: (2013)

Supratentorial Extraventricular Anaplastic Ependymoma Presenting with Repeated Intratumoral Hemorrhage
por: Han, Min-Hee, et al.
Publicado: (2014)

Investigation of Combination Treatment With an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women With Advanced NSCLC
por: Young, Patricia A., et al.
Publicado: (2021)

Immunotherapy of primary methylcholanthrene-induced mouse tumours by intratumoral BCG.
por: Creau-Goldberg, N., et al.
Publicado: (1980)

Addressing the Adult Soft Tissue Sarcoma Microenvironment with Intratumoral Immunotherapy
por: Raj, Shailaja, et al.
Publicado: (2018)

Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST
por: Goldmacher, Gregory V., et al.
Publicado: (2020)

Maximizing response to intratumoral immunotherapy in mice by tuning local retention
por: Momin, Noor, et al.
Publicado: (2022)

Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy
por: Jiang, Xiaoyi, et al.
Publicado: (2022)

Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in EGFR-Mutated NSCLC
por: Kobayashi, Keigo, et al.
Publicado: (2023)

The Role of Interleukin 1β in the Pathogenesis of Lung Cancer
por: Garon, Edward B., et al.
Publicado: (2020)

Recent Advances in Immunotherapy in Metastatic NSCLC
por: Bansal, Pranshu, et al.
Publicado: (2016)

Immunotherapy and NSCLC: The Long and Winding Road
por: Rossi, Antonio
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_r2oohmn142k3mo10eig54qr581